Shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA – Get Free Report) rose 7.5% during mid-day trading on Thursday . The stock traded as high as $0.64 and last traded at $0.63. Approximately 422,022 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 2,335,399 shares. The stock had previously closed at $0.58.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of ZyVersa Therapeutics in a report on Tuesday, March 26th.
Read Our Latest Report on ZyVersa Therapeutics
ZyVersa Therapeutics Price Performance
Institutional Trading of ZyVersa Therapeutics
An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Walleye Capital LLC acquired a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned 3.17% of ZyVersa Therapeutics at the end of the most recent quarter. 3.91% of the stock is owned by hedge funds and other institutional investors.
ZyVersa Therapeutics Company Profile
ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.
Featured Articles
- Five stocks we like better than ZyVersa Therapeutics
- Investing In Automotive Stocks
- Comprehensive PepsiCo Stock Analysis
- How to invest in blue chip stocks
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.